Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
e5RjTXuC1BHuH6Eg
